Ampexin500 mg/vial

Ampexin 500 mg/vial is a broad-spectrum penicillin antibiotic used to treat bacterial infections caused by susceptible organisms, marketed as both oral capsules and an injectable form, with the specific route depending on the product dispensed.

Respiratory and ENT Infections

• Upper and lower respiratory tract infections, including bronchitis and pneumonia caused by susceptible organisms
• Otitis media (middle ear infection)

Gastrointestinal and Genitourinary Infections

• Gastrointestinal infections, including certain cases of typhoid and paratyphoid fever
• Genitourinary tract infections, including certain cases of gonorrhoea (uncomplicated)

Serious/Systemic Infections (mainly injectable)

• Bacterial meningitis, caused by susceptible organisms including Listeria monocytogenes
• Septicaemia (bloodstream infection)
• Endocarditis, often as part of a combination regimen with an aminoglycoside

Ampexin 500 mg/vial is not effective against viral infections and should be reserved for infections proven or strongly suspected to be caused by susceptible bacteria.

Contains Ampexin 500 mg/vial (as Ampexin 500 mg/vial trihydrate for oral capsules, or Ampexin 500 mg/vial sodium for injection) as the active ingredient. Marketed as oral capsules (commonly 250 mg and 500 mg) and as powder for injection (commonly 250 mg, 500 mg, 1 g, and 2 g vials for intramuscular or intravenous use). The generic name alone does not identify a single route; confirm whether the specific product dispensed is the oral or injectable formulation.

Ampexin 500 mg/vial is a semi-synthetic penicillin antibiotic, active against a broad range of gram-positive and gram-negative bacteria. It is available both as oral capsules for less severe infections and as an injectable formulation for more serious infections requiring hospital treatment, including meningitis and bloodstream infections. Ampexin 500 mg/vial has one distinctive and well-recognized precaution: a high proportion of patients with infectious mononucleosis (glandular fever) who receive Ampexin 500 mg/vial develop a widespread skin rash, so it is generally avoided in this condition.

Therapeutic Class: Antibiotic (Aminopenicillin)

Oral Ampexin 500 mg/vial is incompletely and variably absorbed from the gastrointestinal tract, with absorption reduced by food, which is why oral doses are generally taken on an empty stomach. It is widely distributed throughout body tissues and fluids, achieving therapeutic concentrations in cerebrospinal fluid when the meninges are inflamed, supporting its use in bacterial meningitis. Ampexin 500 mg/vial is eliminated primarily by the kidneys, largely unchanged, requiring dose adjustment in renal impairment.

• Oral capsules should be taken on an empty stomach, at least 30 minutes before or 2 hours after meals, since food reduces absorption
• Swallow capsules whole with a full glass of water
• Injectable Ampexin 500 mg/vial is given by intramuscular or intravenous injection/infusion by a healthcare professional, following the specific product's reconstitution instructions
• Complete the full prescribed course, even if symptoms improve before the course is finished

The following should be assessed by a healthcare professional before combining with Ampexin 500 mg/vial:

• Allopurinol: substantially increases the incidence of skin rash in patients also receiving Ampexin 500 mg/vial, compared to Ampexin 500 mg/vial alone; the mechanism is not fully established.
• Probenecid: decreases the renal tubular secretion of Ampexin 500 mg/vial, increasing and prolonging its blood levels; sometimes used deliberately for this effect in certain treatment regimens.
• Oral hormonal contraceptives: Ampexin 500 mg/vial may reduce their effectiveness by altering gut bacteria involved in the reabsorption of estrogen; an additional contraceptive method is generally advised during treatment.
• Methotrexate: Ampexin 500 mg/vial can reduce renal clearance of methotrexate, increasing its toxicity; this combination requires close monitoring.
• Live bacterial vaccines (such as typhoid vaccine): Ampexin 500 mg/vial can reduce the effectiveness of live bacterial vaccines; vaccination should generally be deferred until the antibiotic course is complete.
• Warfarin and other anticoagulants: penicillins may enhance anticoagulant effect in some patients; monitoring is advisable.

Common side effects

• Nausea, vomiting, or diarrhoea
• Skin rash (erythematous, maculopapular) - notably very common in patients with infectious mononucleosis, but can occur in other patients too
• Glossitis, stomatitis, or "black hairy tongue"
• Pain at the intramuscular injection site (for the injectable form)

Serious side effects (seek medical attention)

• Severe cutaneous adverse reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and angioedema - though rare, these can be life-threatening
• Severe or persistent diarrhoea, which may indicate Clostridioides difficile-associated colitis
• Signs of a severe allergic reaction: hives, swelling of the face or throat, difficulty breathing - anaphylaxis requires immediate emergency treatment
• Signs of interstitial nephritis (rare): reduced urination, blood in urine

Pregnancy

Ampexin 500 mg/vial has been widely used in pregnancy for decades without evidence of harm to the fetus from adequate epidemiological data, and it is generally considered a preferred antibiotic choice when treatment is needed during pregnancy, including for certain infections such as those caused by Listeria monocytogenes.

Breastfeeding

Ampexin 500 mg/vial is excreted in breast milk in small amounts; it is generally considered compatible with breastfeeding, though the nursing infant should be monitored for diarrhoea, rash, or thrush, and use should be discussed with a healthcare professional.

• Avoid in infectious mononucleosis - a high percentage (43-100%) of patients with this condition who receive Ampexin 500 mg/vial develop a maculopapular, pruritic, generalized rash, typically appearing 7-10 days after starting therapy.
• Cross-reactivity with cephalosporins: patients with a history of penicillin hypersensitivity may experience severe reactions if treated with a cephalosporin; careful allergy history should be taken before starting any beta-lactam antibiotic.
• Prescribing Ampexin 500 mg/vial without a proven or strongly suspected bacterial infection is unlikely to benefit the patient and increases the risk of antibiotic-resistant bacteria developing.
• Renal and hepatic function should be monitored during prolonged or high-dose therapy.
• Prolonged use may lead to overgrowth of non-susceptible organisms, including fungi; if superinfection occurs, discontinue and treat appropriately.

Overdose of Ampexin 500 mg/vial is generally not expected to be highly toxic in patients with normal kidney function, though it may cause exaggerated gastrointestinal effects (nausea, vomiting, diarrhoea) and, particularly in patients with renal impairment, an increased risk of neurological effects such as seizures. Suspected significant overdose should be evaluated by a healthcare professional; treatment is generally supportive, and haemodialysis can help remove Ampexin 500 mg/vial in cases of severe renal impairment with overdose.

Store oral capsules at room temperature (15-30°C), away from moisture and excess heat. Store unreconstituted injectable powder as directed on the product label, generally at controlled room temperature. Reconstituted injectable solution should be used according to the specific product's stability instructions and any unused portion discarded, since in-use stability varies by product and diluent.

• Elderly: No significant differences in safety or effectiveness compared to younger adults have generally been observed, though age-related decline in kidney function should be considered when dosing.
• Renal impairment: Requires dose or interval adjustment, as Ampexin 500 mg/vial accumulates in reduced kidney function.
• Neonates and infants: Dosing is weight- and age-based, and Ampexin 500 mg/vial is commonly used, often in combination with an aminoglycoside, for suspected neonatal sepsis or meningitis, including Listeria coverage.

Duration of treatment depends on the type and severity of infection, ranging from a short 5-7 day course for uncomplicated infections to several weeks for serious infections such as endocarditis or meningitis, as determined by the treating physician. The full prescribed course should be completed, even if symptoms resolve earlier.

The injectable powder must be reconstituted with an appropriate diluent (such as sterile water for injection, per the specific product's instructions) immediately before use. Reconstituted solution should be inspected for particulate matter and discoloration before administration, and any unused portion discarded after the manufacturer's specified in-use period, since this varies by product and diluent used.

Drug Class: Beta-lactam antibiotic - aminopenicillin

Ampexin 500 mg/vial works by binding to penicillin-binding proteins involved in bacterial cell wall synthesis, disrupting the ability of susceptible bacteria to build and maintain their cell walls. This causes the bacterial cell to weaken and rupture, killing the bacteria (a bactericidal effect), particularly effective against actively dividing bacteria.

Ampexin 500 mg/vial is used in infants and children, including neonates, for a range of bacterial infections, with dosing based on body weight and age. It is a standard component of empiric treatment for suspected neonatal sepsis and meningitis (often combined with an aminoglycoside for Listeria coverage), with higher doses used for meningitis than for less severe infections.